Ambrisentan
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 505 publications
Marked clinical and haemodynamic improvement with sotatercept in severe refractory pulmonary arterial hypertension associated with corrected complex congenital heart disease.
Journal: Respiratory medicine case reports
Published: January 22, 2026
Pulmonary Artery Denervation for Refractory Sjögren's Syndrome-Associated Pulmonary Arterial Hypertension: A Case Report of Combined Hemodynamic and Renal Recovery.
Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
Published: December 09, 2025
Endothelin Receptor Antagonist Ambrisentan, SGLT2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial.
Journal: Journal of the American Society of Nephrology : JASN
Published: October 10, 2025
Breath-activated nanomedicine: Ambrisentan-loaded chitosomes for pulmonary arterial hypertension.
Journal: International journal of pharmaceutics
Published: October 06, 2025
Endothelin-1 in the failing Fontan: pathobiology, precision therapeutics, and future trial design.
Journal: Frontiers in pediatrics
Published: October 03, 2025
Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS).
Journal: Frontiers in cardiovascular medicine
Published: September 25, 2025
Ambrisentan ameliorates methotrexate-induced pulmonary injury in rats: involvement of ET-1/ETA, NF-κB, and MMP-9/TIMP-1 pathways.
Journal: Toxicology and applied pharmacology
Published: September 20, 2025
Pathogenic Glomulin Gene Variant in a Patient with Idiopathic Pulmonary Arterial Hypertension: A Novel Association Case Report.
Journal: Reports (MDPI)
Published: September 16, 2025
Transitioning From Oral to Intravenous Treprostinil in Pulmonary Arterial Hypertension: A Case Report.
Journal: Clinical case reports
Published: September 12, 2025
Tadalafil for Treatment of Pulmonary Hypertension: Mechanisms, Evidence, and Emerging Perspectives.
Journal: Cardiology in review
Published: September 11, 2025
In brief: Embryotoxicity REMS removal for endothelin receptor antagonists.
Journal: The Medical letter on drugs and therapeutics
Published: September 09, 2025
Last Updated: 04/28/2026